# Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer

> **NCT01605318** · PHASE1,PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 92 (actual)

## Conditions studied

- Metastatic Colorectal Cancer
- Colon Cancer
- Rectal Cancer

## Interventions

- **DRUG:** Labetuzumab Govitecan (LG)

## Key facts

- **NCT ID:** NCT01605318
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-02-12
- **Primary completion:** 2017-01-03
- **Final completion:** 2017-01-03
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2024-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01605318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01605318, "Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01605318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*